No Data
HERVolution Appoints Dr. Tine Gaziel as CMO to Advance Dark Genome-Targeting Immune Therapy Into the Clinic
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $37
Genmab's Strong Market Position and Growth Potential Justifies Buy Rating
Genmab Advances Share Buy-back Program With Significant Repurchases
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Geron (GERN), Genmab (GMAB) and Elanco Animal Health (ELAN)
Lnova : whoa!